Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) – Investment analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Cyclo Therapeutics in a report released on Wednesday, May 1st. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.20) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for Cyclo Therapeutics’ current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Cyclo Therapeutics’ Q2 2024 earnings at ($0.16) EPS, Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.64) EPS, Q1 2025 earnings at ($0.14) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.47) EPS and FY2027 earnings at ($0.38) EPS.
Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) last released its quarterly earnings data on Monday, March 18th. The company reported ($0.23) earnings per share for the quarter. Cyclo Therapeutics had a negative return on equity of 4,506.97% and a negative net margin of 1,864.03%. The business had revenue of $0.31 million during the quarter.
Check Out Our Latest Report on Cyclo Therapeutics
Cyclo Therapeutics Stock Performance
NASDAQ:CYTH opened at $1.51 on Friday. The firm has a 50-day simple moving average of $1.45 and a 200-day simple moving average of $1.47. Cyclo Therapeutics has a one year low of $0.89 and a one year high of $2.57. The firm has a market cap of $43.37 million, a P/E ratio of -1.15 and a beta of -0.18.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund V Management LLC bought a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH – Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics comprises 80.8% of Founders Fund V Management LLC’s holdings, making the stock its biggest position. Founders Fund V Management LLC owned 2.11% of Cyclo Therapeutics as of its most recent filing with the SEC. 68.55% of the stock is currently owned by hedge funds and other institutional investors.
Cyclo Therapeutics Company Profile
Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.
Featured Articles
- Five stocks we like better than Cyclo Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- MarketBeat Week in Review – 4/29 – 5/3
- Short Selling: How to Short a Stock
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What is a Secondary Public Offering? What Investors Need to Know
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.